Novartis Investors Turn Spotlight on M&A After Trial Setbacks

3-line summary

• Novartis investors turned their spotlight on M&A after recent trial setbacks, according to an Investing.com report.
• This follows earlier reports of a failed cholesterol drug trial and a major shareholder's call for a board shake-up.

This summary is our own processing of the source article; see the source link below for full context.